HomeBUSINESS
BUSINESS

Zytiga Shows Consistent Efficacy in Japanese High-Risk mHNPC Patients
(Feb.14.2018)

Janssen Pharmaceutical’s prostate cancer drug Zytiga (abiraterone) plus low-dose prednisone and androgen deprivation therapy (ADT) showed consistent efficacy in Japanese metastatic, hormone-naïve prostate cancer (mHNPC) patients compared to the overall population in a key global PIII study, dubbed LATITUDE ...
(LOG IN FOR FULL STORY)

News Calendar